|Year : 2021 | Volume
| Issue : 2 | Page : 67
Covid era and cancer care
Amal Chandra Kataki
Gyaenecological Oncology, Dr. B Borooah Cancer Institute, Guwahati, Assam, India
|Date of Submission||02-Dec-2021|
|Date of Acceptance||02-Dec-2021|
|Date of Web Publication||22-Dec-2021|
Dr. Amal Chandra Kataki
Dr. B Borooah Cancer Institute, Guwahati - 781 016, Assam
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Kataki AC. Covid era and cancer care. Ann Oncol Res Ther 2021;1:67
Health care has been traditionally immune to disruptive forces until the coronavirus disease-2019 (COVID-19) global pandemic in 2020. This pandemic highlighted the shortcomings of our current health-care system, setting the stage for transformational changes. It is important to balance the risk of acquiring COVID-19 in patients with cancer and continue treatment with minor modification in the treatment regime. Also, it is imperative to protect the healthcare workers from acquiring COVID-19 and continue to allow them to take care of the sick patients with cancer, which posed a challenge to healthcare administrators.
Cancer care has been disproportionately impacted by this pandemic, from preventive care to treatment and patient follow-up, which may lead to later-stage cancers for patients and increasing patient morbidity and mortality as well as regression in the strides made in cancer care and overall patient survival.
At the same time, the pandemic has become a catalyst for the widespread and rapid adoption of strategies that had been in the wings, such as telemedicine, virtual care, and new payment models, in addition to cross-collaborations that likely would have taken years to implement.
At Dr. B Borooah Cancer Institute, Guwahati, we maximize the use of telemedicine, systematic screening of patients, vaccination of health-care personnel, impetus on hygiene, usage of face masks and shields, virtual tumor-boards as well as effective use of technology in information transfer, thereby minimizing contact transfer of pathogens. Our strategies have been varied and effective, but as we draw toward the end of 2021, we are waking up to new variants such as the Delta and Omicron. This is a siren call to us that the war against this virus is far from over.
The lessons we learned in the past 2 years should be our guidance ahead as various governments and institutional bodies formulate dynamic standard operating procedures. India is targeting 60% of the population to be vaccinated with both the doses by December 2021. The mutated variants may not respond to the vaccines which are formulated on the primary strains, and hence, this will keep the quest to find a silver bullet wide open. Meanwhile, it is prudent that we all keep our vigil with a healthy lifestyle, follow physical distance, and use face masks in indoor settings.
It may so happen that the COVID-19 virus may be something we all have to live with and the success of it can solely depend on our adaptability and acceptance.
I wish you all a happy and prosperous new year 2022.